AVIEW LCS vs AVIEW Lung Nodule CAD

Direct competitors — feature-level head-to-head below. Comparability 98/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
by Coreline Soft Co.
VS
by Coreline Soft Co.

AI Verdict

These two tools, both from Coreline Soft Co., are highly comparable as they offer nearly identical AI-powered capabilities for lung nodule detection, emphysema quantification, and coronary artery calcification scoring from CT scans. While AVIEW LCS is presented as a broader "Plus platform" for integrated analysis, AVIEW Lung Nodule CAD focuses on assisting radiologists with specific nodule detection and analysis, suggesting they may be different iterations or modules of the same core technology.

Choose AVIEW LCS if…

Choose AVIEW LCS if your institution seeks a highly automated and integrated platform for comprehensive lung cancer screening programs and cardiopulmonary assessment. This solution is ideal for streamlining radiology workflows by providing fully automatic analysis of lung cancer, COPD, and coronary artery calcification from a single low-dose CT scan, including automated comparisons for follow-up and comprehensive report generation.

View AVIEW LCS →

Choose AVIEW Lung Nodule CAD if…

Choose AVIEW Lung Nodule CAD if radiologists require an AI-powered assistant to enhance their detection and analysis of pulmonary nodules on chest CT scans. This tool is best suited for providing adjunctive information to radiologists, offering detailed nodule characterization, classification, and volume quantification, while simultaneously supporting comprehensive screening for lung cancer, COPD, and coronary artery calcification within the radiologist's diagnostic workflow.

View AVIEW Lung Nodule CAD →

When choosing between AVIEW LCS and AVIEW Lung Nodule CAD, physicians should consider their primary focus and desired level of comprehensive analysis. Both tools, developed by Coreline Soft, offer AI-powered assistance for detecting and analyzing pulmonary nodules on chest CT scans, and both include features for lung cancer screening, COPD assessment, and coronary artery calcification analysis. They are also both HIPAA compliant and FDA cleared, with flexible deployment options.

The key practical difference lies in their scope and specific feature sets. AVIEW LCS, particularly the ‘Plus’ platform, emphasizes an integrated and fully automatic analysis of lung cancer, COPD, and coronary artery calcification from a single low-dose CT scan. It highlights features like Lung-RADS classification and reporting, nodule volume quantification, emphysema quantification (LAA index), and comprehensive CAC scoring (Agatston, volume, mass). AVIEW Lung Nodule CAD, while also offering comprehensive screening for the ‘Big 3’ (lung nodules, emphysema, and coronary artery calcification), specifically details AI-based pulmonary nodule detection for nodules 3-20 mm, nodule classification (solid, part-solid, non-solid), and volume doubling time (VDT) calculation for follow-up comparisons.

Therefore, a physician prioritizing a highly integrated, fully automatic, and comprehensive cardiopulmonary assessment from a single low-dose CT scan, with a strong emphasis on detailed reporting and workflow streamlining, might lean towards AVIEW LCS. Conversely, a physician whose primary need is robust AI-assisted pulmonary nodule detection with specific size parameters (3-20mm), detailed nodule classification, and volume doubling time calculations for follow-up, while still benefiting from the ‘Big 3’ analysis, may find AVIEW Lung Nodule CAD to be a more precise fit for their workflow.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature AVIEW LCS AVIEW Lung Nodule CAD
Pricing Contact for pricing Contact for pricing
Deployment Cloud-based, Hybrid solution, Locally on dedicated hardware, Locally virtualized (virtual machine, Docker) Cloud-based, Hybrid solution, Locally on dedicated hardware, Locally virtualized (virtual machine, Docker)
FDA Status 1 AI-estimated 1 AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Tie

Both tools are designed to streamline radiology workflows through automation and integration, aiming to enhance diagnostic efficiency. While one source suggests Tool B highlights workflow automation more explicitly, other descriptions of Tool A (LCS Plus) emphasize integrated, fully automatic analysis and workflow streamlining, making it difficult to distinguish a clear winner in overall usability.

Clinical Value

AVIEW Lung Nodule CAD

While both tools offer strong clinical value with similar core features for lung nodule detection, emphysema, and CAC scoring, Tool B (AVIEW Lung Nodule CAD) explicitly cites impressive clinical performance metrics. It demonstrated a 34% increase in lung nodule detection sensitivity, a 42% decrease in false positives, and a 70% reduction in reading time, providing quantifiable evidence of enhanced clinical utility.

Pricing & Value

AVIEW LCS

Both tools require direct contact for pricing, but external information for AVIEW LCS Plus (Tool A) explicitly outlines potential pricing models, including one-off payments or subscriptions based on installations or users. This offers slightly more transparency regarding potential cost structures compared to Tool B's general statement about industry pricing models.

Enterprise Readiness

AVIEW LCS

Both tools demonstrate strong enterprise readiness with FDA clearance, HIPAA compliance, and flexible deployment options. However, Tool A explicitly states the availability of a Business Associate Agreement (BAA) in its specifications. Furthermore, the AVIEW LCS Plus platform, which Tool A is a part of, integrates with AVIEW Hub for advanced multi-site workflow management, GDPR compliance, and consensus processes, indicating a more comprehensive enterprise solution. [cite: 34, JSON]

Innovation

Tie

Both tools originate from the same company and share the core innovative 'Big 3' integrated analysis of lung nodules, emphysema, and coronary artery calcification from a single CT scan. While Tool A emphasizes 'fully automatic analysis' and 'CT kernel conversion AI technology,' Tool B's recent FDA clearance renewal for meeting strengthened cybersecurity criteria represents an innovation in regulatory compliance. Given their shared technological foundation and similar advanced features, neither demonstrates a clearly superior innovative edge over the other.

Support & Docs

Tie

As both AVIEW LCS and AVIEW Lung Nodule CAD are products of Coreline Soft Co., they would inherently share the same customer service team, contact information, and general support resources provided by the parent company. No specific product-level differences in support or documentation are indicated.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature AVIEW LCS AVIEW Lung Nodule CAD
Name AVIEW LCS AVIEW Lung Nodule CAD
Company Coreline Soft Co. Coreline Soft Co.
Tagline AI-Powered Lung Cancer Screening & Cardiopulmonary Assessment Advancing Radiology with AI
Description Coreline Soft's AVIEW LCS is an AI-powered solution for the detection and analysis of lung nodules. The AVIEW LCS Plus platform provides integrated, fully automatic analysis of lung cancer, COPD, and coronary artery calcification from a single low-dose CT scan, enhancing diagnostic accuracy and streamlining radiology workflows. AVIEW Lung Nodule CAD is an AI-powered software by Coreline Soft Co. that assists radiologists in detecting and analyzing pulmonary nodules on chest CT scans, and offers comprehensive screening for lung cancer, COPD, and coronary artery calcification.
Key Features (Lung Nodule Analysis) Automated lung nodule detection and analysis, Lung-RADS classification and reporting, Nodule volume quantification and 3D segmentation, Automated comparison of nodules in follow-up CT scans AI-based pulmonary nodule detection (3-20 mm) on CT scans, Nodule classification (solid, part-solid, non-solid), 3D nodule size and volume quantification, Automatic report generation based on Lung-RADS classification, Nodule matching and volume doubling time (VDT) calculation for follow-up comparisons
Key Features (Cardiopulmonary Assessment) Emphysema quantification (LAA index), Coronary Artery Calcification (CAC) scoring (Agatston, volume, mass) Simultaneous analysis of lung nodules, emphysema, and coronary artery calcification (Big 3), Quantitative emphysema analysis (e.g., Low Attenuation Area - LAA, emphysema index), Coronary Artery Calcification (CAC) scoring (Agatston, volume, mass scores)

Videos

Demos, reviews, and walkthroughs featuring AVIEW LCS and AVIEW Lung Nodule CAD.

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

AVIEW LCS, particularly the AVIEW LCS Plus platform, is described as providing integrated, fully automatic analysis of lung cancer, COPD, and coronary artery calcification from a single low-dose CT scan. AVIEW Lung Nodule CAD is an AI-powered software that assists radiologists in detecting and analyzing pulmonary nodules and offers comprehensive screening for these conditions, explicitly mentioning simultaneous analysis of the 'Big 3' components.
AVIEW Lung Nodule CAD specifies AI-based pulmonary nodule detection for nodules between 3-20 mm, offering explicit nodule classification (solid, part-solid, non-solid) and volume doubling time (VDT) calculation for follow-up. AVIEW LCS provides automated nodule detection and analysis, including 3D segmentation and automated comparison of nodules in follow-up CT scans.
AVIEW LCS explicitly lists 'Integration with PACS/RIS and third-party platforms' as a key feature. While not explicitly detailed in the provided features for AVIEW Lung Nodule CAD, such integration is a common requirement for radiology AI solutions.
Both AVIEW LCS and AVIEW Lung Nodule CAD provide emphysema quantification (LAA index) and Coronary Artery Calcification (CAC) scoring (Agatston, volume, mass). AVIEW Lung Nodule CAD additionally mentions 'emphysema index' as part of its quantitative emphysema analysis.
AI Tool Finder
AI-powered search. Results may not be comprehensive.